首页 > 最新文献

Advances in respiratory medicine最新文献

英文 中文
Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. 法匹拉韦治疗门诊COVID-19:一项多中心、随机、三盲、安慰剂对照临床试验
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-01-28 DOI: 10.3390/arm91010004
Atefeh Vaezi, Mehrzad Salmasi, Forogh Soltaninejad, Mehrdad Salahi, Shaghayegh Haghjooy Javanmard, Babak Amra

Background: Finding effective outpatient treatments to prevent COVID-19 progression and hospitalization is necessary and is helpful in managing limited hospital resources. Repurposing previously existing treatments is highly desirable. In this study, we evaluate the efficacy of Favipiravir in the prevention of hospitalization in symptomatic COVID-19 patients who were not eligible for hospitalization.

Methods: This study was a triple-blind randomized controlled trial conducted between 5 December 2020 and 31 March 2021 in three outpatient centers in Isfahan, Iran. Patients in the intervention group received Favipiravir 1600 mg daily for five days, and the control group received a placebo. Our primary outcome was the proportion of hospitalized participants from day 0 to day 28. The outcome was assessed on days 3, 7, 14, 21, and 28 through phone calls.

Results: Seventy-seven patients were randomly allocated to Favipiravir and placebo groups. There was no significant difference between groups considering baseline characteristics. During the study period, 10.5% of patients in the Favipiravir group and 5.1% of patients in the placebo group were hospitalized, but there was no significant difference between them (p-value = 0.3). No adverse event was reported in the treatment group.

Conclusions: Our study shows that Favipiravir did not reduce the hospitalization rate of mild to moderate COVID-19 patients in outpatient settings.

背景:寻找有效的门诊治疗方法预防COVID-19进展和住院是必要的,有助于管理有限的医院资源。重新利用先前存在的治疗方法是非常可取的。在本研究中,我们评估了Favipiravir在不符合住院条件的有症状的COVID-19患者中预防住院的疗效。方法:本研究是一项三盲随机对照试验,于2020年12月5日至2021年3月31日在伊朗伊斯法罕的三个门诊中心进行。干预组患者每天服用1600mg Favipiravir,连续5天,对照组患者服用安慰剂。我们的主要结局是从第0天到第28天住院参与者的比例。在第3天、第7天、第14天、第21天和第28天通过电话评估结果。结果:77例患者随机分为法匹拉韦组和安慰剂组。考虑基线特征,两组间无显著差异。在研究期间,Favipiravir组10.5%的患者住院,安慰剂组5.1%的患者住院,但两者之间无显著差异(p值= 0.3)。治疗组无不良事件发生。结论:我们的研究表明,Favipiravir并没有降低门诊轻中度COVID-19患者的住院率。
{"title":"Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial.","authors":"Atefeh Vaezi,&nbsp;Mehrzad Salmasi,&nbsp;Forogh Soltaninejad,&nbsp;Mehrdad Salahi,&nbsp;Shaghayegh Haghjooy Javanmard,&nbsp;Babak Amra","doi":"10.3390/arm91010004","DOIUrl":"https://doi.org/10.3390/arm91010004","url":null,"abstract":"<p><strong>Background: </strong>Finding effective outpatient treatments to prevent COVID-19 progression and hospitalization is necessary and is helpful in managing limited hospital resources. Repurposing previously existing treatments is highly desirable. In this study, we evaluate the efficacy of Favipiravir in the prevention of hospitalization in symptomatic COVID-19 patients who were not eligible for hospitalization.</p><p><strong>Methods: </strong>This study was a triple-blind randomized controlled trial conducted between 5 December 2020 and 31 March 2021 in three outpatient centers in Isfahan, Iran. Patients in the intervention group received Favipiravir 1600 mg daily for five days, and the control group received a placebo. Our primary outcome was the proportion of hospitalized participants from day 0 to day 28. The outcome was assessed on days 3, 7, 14, 21, and 28 through phone calls.</p><p><strong>Results: </strong>Seventy-seven patients were randomly allocated to Favipiravir and placebo groups. There was no significant difference between groups considering baseline characteristics. During the study period, 10.5% of patients in the Favipiravir group and 5.1% of patients in the placebo group were hospitalized, but there was no significant difference between them (<i>p</i>-value = 0.3). No adverse event was reported in the treatment group.</p><p><strong>Conclusions: </strong>Our study shows that Favipiravir did not reduce the hospitalization rate of mild to moderate COVID-19 patients in outpatient settings.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 1","pages":"18-25"},"PeriodicalIF":1.8,"publicationDate":"2023-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10791804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Acknowledgment to the Reviewers of Advances in Respiratory Medicine in 2022. 对2022年呼吸医学进展评审员的致谢。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-01-18 DOI: 10.3390/arm91010002
Advance In Respiratory Medicine Editorial Office

High-quality academic publishing is built on rigorous peer review [...].

高质量的学术出版建立在严格的同行评议之上[…]。
{"title":"Acknowledgment to the Reviewers of <i>Advances in Respiratory Medicine</i> in 2022.","authors":"Advance In Respiratory Medicine Editorial Office","doi":"10.3390/arm91010002","DOIUrl":"https://doi.org/10.3390/arm91010002","url":null,"abstract":"<p><p>High-quality academic publishing is built on rigorous peer review [...].</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 1","pages":"9-10"},"PeriodicalIF":1.8,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10791802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suspected Lung Cancer with Suspicious Liver Lesions: Diagnostic Yield and Safety of Same-Day Bronchoscopy and Liver Biopsy in the Hands of a Pulmonologist. 疑似肺癌伴可疑肝脏病变:肺科医生当日支气管镜检查和肝活检的诊断率和安全性。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-01-18 DOI: 10.3390/arm91010003
Sina Ahmadzai, Jesper Koefod Petersen, Katrine Fjaellegaard, Paul Frost Clementsen, Uffe Bodtger

Background: Bronchoscopy and endobronchial ultrasound (EBUS) are standard procedures for the diagnosis and staging of patients suspected of lung cancer. If the patient simultaneously presents with suspicious liver lesions, it is tradition to refer the patient to a radiologist for ultrasound-guided percutaneous liver biopsy.

Objective: The aim of this study was to investigate the results and complications when the pulmonologist performs all three procedures in the same setting.

Methods: We retrospectively identified patients who during 2018-2020 underwent invasive workup of suspected lung cancer and liver metastases with percutaneous liver lesion biopsy with or without same-day endoscopy (bronchoscopy and EBUS). We compared diagnostic yield and safety of liver lesion biopsy stratified by same-day endoscopy or not.

Results: In total, 89 patients were included, of whom 28 patients (31%) underwent same-day endoscopy. All liver lesion biopsies were fine-needle aspiration biopsies performed by experienced pulmonologists. No complications were reported, and overall diagnostic yield was 88%. The diagnostic yield was significantly lower in the same-day endoscopy group (71% vs. 95%), and undergoing endoscopy was significantly associated with having fewer liver lesions, higher prevalence of lung cancer, and lower overall prevalence of a malignant diagnosis.

Conclusion: Liver biopsy in the same session as endoscopy during lung cancer workup was feasible and safe. Confounding by indication was present in our study.

背景:支气管镜检查和支气管超声检查(EBUS)是诊断和分期疑似肺癌患者的标准程序。如果患者同时出现可疑的肝脏病变,传统的做法是将患者转介给放射科医生进行超声引导下的经皮肝活检。目的:本研究的目的是调查肺科医生在同一环境下进行这三种手术的结果和并发症。方法:回顾性分析2018-2020年期间接受了有创性检查的疑似肺癌和肝转移患者,并进行了经皮肝病变活检,有或没有当日内镜检查(支气管镜检查和EBUS)。我们比较了当日内镜和非当日内镜分层肝病变活检的诊断率和安全性。结果:共纳入89例患者,其中28例(31%)当日行内镜检查。所有肝病变活检均由经验丰富的肺科医生进行细针穿刺活检。无并发症报告,总诊断率为88%。当天内镜检查组的诊断率明显较低(71%对95%),并且接受内镜检查与肝脏病变较少、肺癌患病率较高和恶性诊断总体患病率较低显著相关。结论:在肺癌检查中,肝活检与内窥镜检查同时进行是可行和安全的。在我们的研究中存在指征混淆。
{"title":"Suspected Lung Cancer with Suspicious Liver Lesions: Diagnostic Yield and Safety of Same-Day Bronchoscopy and Liver Biopsy in the Hands of a Pulmonologist.","authors":"Sina Ahmadzai,&nbsp;Jesper Koefod Petersen,&nbsp;Katrine Fjaellegaard,&nbsp;Paul Frost Clementsen,&nbsp;Uffe Bodtger","doi":"10.3390/arm91010003","DOIUrl":"https://doi.org/10.3390/arm91010003","url":null,"abstract":"<p><strong>Background: </strong>Bronchoscopy and endobronchial ultrasound (EBUS) are standard procedures for the diagnosis and staging of patients suspected of lung cancer. If the patient simultaneously presents with suspicious liver lesions, it is tradition to refer the patient to a radiologist for ultrasound-guided percutaneous liver biopsy.</p><p><strong>Objective: </strong>The aim of this study was to investigate the results and complications when the pulmonologist performs all three procedures in the same setting.</p><p><strong>Methods: </strong>We retrospectively identified patients who during 2018-2020 underwent invasive workup of suspected lung cancer and liver metastases with percutaneous liver lesion biopsy with or without same-day endoscopy (bronchoscopy and EBUS). We compared diagnostic yield and safety of liver lesion biopsy stratified by same-day endoscopy or not.</p><p><strong>Results: </strong>In total, 89 patients were included, of whom 28 patients (31%) underwent same-day endoscopy. All liver lesion biopsies were fine-needle aspiration biopsies performed by experienced pulmonologists. No complications were reported, and overall diagnostic yield was 88%. The diagnostic yield was significantly lower in the same-day endoscopy group (71% vs. 95%), and undergoing endoscopy was significantly associated with having fewer liver lesions, higher prevalence of lung cancer, and lower overall prevalence of a malignant diagnosis.</p><p><strong>Conclusion: </strong>Liver biopsy in the same session as endoscopy during lung cancer workup was feasible and safe. Confounding by indication was present in our study.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 1","pages":"11-17"},"PeriodicalIF":1.8,"publicationDate":"2023-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10791803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic Accuracy of Slow-Capillary Endobronchial Ultrasound Needle Aspiration in Determining PD-L1 Expression in Non-Small Cell Lung Cancer. 慢毛细支气管内超声针吸检测非小细胞肺癌PD-L1表达的诊断准确性。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2023-01-12 DOI: 10.3390/arm91010001
Lina Zuccatosta, Federico Mei, Michele Sediari, Alessandro Di Marco Berardino, Martina Bonifazi, Francesca Barbisan, Gaia Goteri, Stefano Gasparini, Francesca Gonnelli

Introduction: The role of EBUS-TBNA in the diagnosis and staging of lung cancer is well established. EBUS-TBNA can be performed using different aspiration techniques. The most common aspiration technique is known as "suction". One alternative to the suction technique is the slow-pull capillary aspiration. To the best of our knowledge, no studies have assessed the diagnostic yield of slow-pull capillary EBUS-TBNA in PD-L1 amplification assessment in NSCLC. Herein, we conducted a single-centre retrospective study to establish the diagnostic yield of slow-pull capillary EBUS-TBNA in terms of PD-L1 in patients with NSCLC and hilar/mediastinal lymphadenopathies subsequent to NSCLC.

Materials and methods: Patients with hilar and/or mediastinal lymph node (LN) NSCLC metastasis, diagnosed by EBUS-TBNA between January 2021 and April 2022 at Pulmonology Unit of "Ospedali Riuniti di Ancona" (Ancona, Italy) were enrolled. We evaluated patient characteristics, including demographic information, CT scan/ FDG-PET features and final histological diagnoses, including PD-L1 assessment.

Results: A total of 174 patients underwent EBUS-TBNA for diagnosis of hilar/mediastinal lymphadenopathies between January 2021 and April 2022 in the Interventional Pulmonology Unit of the "Ospedali Riuniti di Ancona". Slow-pull capillary aspiration was adopted in 60 patients (34.5%), and in 30/60 patients (50.0%) NSCLC was diagnosed. EBUS-TBNA with slow-pull capillary aspiration provided adequate sampling for molecular biology and PD-L1 testing in 96.7% of patients (29/30); in 15/29 (51.7%) samples with more than 1000 viable cells/HPF were identified, whereas in 14/29 (48.3%) samples contained 101-1000 viable cells/HPF.

Conclusion: These retrospective study shows that slow-pull capillary aspiration carries an excellent diagnostic accuracy, almost equal to that one reported in literature, supporting its use in EBUS-TBNA for PD-L1 testing in NSCLC.

EBUS-TBNA在肺癌的诊断和分期中的作用已经得到了很好的证实。EBUS-TBNA可以使用不同的吸入技术进行。最常见的抽吸技术是“抽吸”。另一种抽吸技术是慢拉式毛细管抽吸。据我们所知,目前还没有研究评估慢拉毛细血管EBUS-TBNA在非小细胞肺癌PD-L1扩增评估中的诊断率。在此,我们进行了一项单中心回顾性研究,以确定慢拉毛细血管EBUS-TBNA对非小细胞肺癌和肺门/纵隔淋巴结病变患者PD-L1的诊断率。材料和方法:入选2021年1月至2022年4月在意大利安科纳(Ancona, Italy)“Ospedali Riuniti di Ancona”肺病科通过EBUS-TBNA诊断的肺门和/或纵隔淋巴结(LN) NSCLC转移患者。我们评估了患者的特征,包括人口统计学信息、CT扫描/ FDG-PET特征和最终的组织学诊断,包括PD-L1评估。结果:2021年1月至2022年4月,共有174例患者在安科纳国立医院介入肺科接受了EBUS-TBNA诊断肺门/纵隔淋巴结病。60例(34.5%)患者采用慢拉式毛细管抽吸,其中30/60例(50.0%)患者被诊断为NSCLC。96.7%的患者(29/30)采用慢拉式毛细管抽吸EBUS-TBNA为分子生物学和PD-L1检测提供了足够的样本;15/29(51.7%)的样品活细胞/HPF大于1000个,14/29(48.3%)的样品活细胞/HPF为101 ~ 1000个。结论:本回顾性研究显示,慢拉式毛细管抽吸具有极好的诊断准确性,几乎与文献报道的诊断准确性相当,支持将其用于EBUS-TBNA检测非小细胞肺癌的PD-L1。
{"title":"Diagnostic Accuracy of Slow-Capillary Endobronchial Ultrasound Needle Aspiration in Determining PD-L1 Expression in Non-Small Cell Lung Cancer.","authors":"Lina Zuccatosta,&nbsp;Federico Mei,&nbsp;Michele Sediari,&nbsp;Alessandro Di Marco Berardino,&nbsp;Martina Bonifazi,&nbsp;Francesca Barbisan,&nbsp;Gaia Goteri,&nbsp;Stefano Gasparini,&nbsp;Francesca Gonnelli","doi":"10.3390/arm91010001","DOIUrl":"https://doi.org/10.3390/arm91010001","url":null,"abstract":"<p><strong>Introduction: </strong>The role of EBUS-TBNA in the diagnosis and staging of lung cancer is well established. EBUS-TBNA can be performed using different aspiration techniques. The most common aspiration technique is known as \"suction\". One alternative to the suction technique is the slow-pull capillary aspiration. To the best of our knowledge, no studies have assessed the diagnostic yield of slow-pull capillary EBUS-TBNA in PD-L1 amplification assessment in NSCLC. Herein, we conducted a single-centre retrospective study to establish the diagnostic yield of slow-pull capillary EBUS-TBNA in terms of PD-L1 in patients with NSCLC and hilar/mediastinal lymphadenopathies subsequent to NSCLC.</p><p><strong>Materials and methods: </strong>Patients with hilar and/or mediastinal lymph node (LN) NSCLC metastasis, diagnosed by EBUS-TBNA between January 2021 and April 2022 at Pulmonology Unit of \"Ospedali Riuniti di Ancona\" (Ancona, Italy) were enrolled. We evaluated patient characteristics, including demographic information, CT scan/ FDG-PET features and final histological diagnoses, including PD-L1 assessment.</p><p><strong>Results: </strong>A total of 174 patients underwent EBUS-TBNA for diagnosis of hilar/mediastinal lymphadenopathies between January 2021 and April 2022 in the Interventional Pulmonology Unit of the \"Ospedali Riuniti di Ancona\". Slow-pull capillary aspiration was adopted in 60 patients (34.5%), and in 30/60 patients (50.0%) NSCLC was diagnosed. EBUS-TBNA with slow-pull capillary aspiration provided adequate sampling for molecular biology and PD-L1 testing in 96.7% of patients (29/30); in 15/29 (51.7%) samples with more than 1000 viable cells/HPF were identified, whereas in 14/29 (48.3%) samples contained 101-1000 viable cells/HPF.</p><p><strong>Conclusion: </strong>These retrospective study shows that slow-pull capillary aspiration carries an excellent diagnostic accuracy, almost equal to that one reported in literature, supporting its use in EBUS-TBNA for PD-L1 testing in NSCLC.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"91 1","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2023-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10553983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Peritoneal Oxygenation as a Novel Technique for Extrapulmonary Ventilation; A Review and Discussion of the Literature. 腹膜氧合作为肺外通气的新技术文献回顾与讨论。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-12-12 DOI: 10.3390/arm90060057
James R M Colbourne, Khaled H Altoukhi, David L Morris

The COVID-19 crisis has highlighted the difficulties that might occur when attempting to oxygenate patients who have suffered a severe pulmonary insult, including in the development of acute respiratory distress syndrome (ARDS). Traditional mechanical ventilation (MV) is effective; however, in severe cases of hypoxia, the use of rescue therapy, such as extracorporeal membrane oxygenation (ECMO), may be required but is also associated with significant complexity and complications. In this review, we describe peritoneal oxygenation; a method of oxygenation that exploits the peritoneum's gas exchange properties in a fashion that is similar to peritoneal dialysis and has shown considerable promise in animal models. We have conducted a review of the available literature and techniques, including intraperitoneal perfluorocarbons, intraperitoneal jet ventilation, a continuous low-pressure oxygen system (PEROX) and the use of phospholipid-coated oxygen microbubbles (OMBs) through peritoneal microbubble oxygenation (PMO). We conclude that peritoneal oxygenation is a promising technique that warrants further investigation and might be used in clinical settings in the future.

COVID-19危机凸显了在试图为遭受严重肺损伤的患者(包括急性呼吸窘迫综合征)提供氧气时可能出现的困难。传统机械通气(MV)是有效的;然而,在严重缺氧的情况下,可能需要使用抢救治疗,如体外膜氧合(ECMO),但也与显著的复杂性和并发症相关。在这篇综述中,我们描述了腹膜氧合;一种利用腹膜气体交换特性的氧合方法,类似于腹膜透析,在动物模型中显示出相当大的前景。我们对现有的文献和技术进行了综述,包括腹腔内全氟碳化合物、腹腔内喷射通气、连续低压氧系统(PEROX)和通过腹膜微泡氧合(PMO)使用磷脂包被氧微泡(OMBs)。我们的结论是,腹膜氧合是一种有前途的技术,值得进一步研究,并可能在未来的临床环境中使用。
{"title":"Peritoneal Oxygenation as a Novel Technique for Extrapulmonary Ventilation; A Review and Discussion of the Literature.","authors":"James R M Colbourne,&nbsp;Khaled H Altoukhi,&nbsp;David L Morris","doi":"10.3390/arm90060057","DOIUrl":"https://doi.org/10.3390/arm90060057","url":null,"abstract":"<p><p>The COVID-19 crisis has highlighted the difficulties that might occur when attempting to oxygenate patients who have suffered a severe pulmonary insult, including in the development of acute respiratory distress syndrome (ARDS). Traditional mechanical ventilation (MV) is effective; however, in severe cases of hypoxia, the use of rescue therapy, such as extracorporeal membrane oxygenation (ECMO), may be required but is also associated with significant complexity and complications. In this review, we describe peritoneal oxygenation; a method of oxygenation that exploits the peritoneum's gas exchange properties in a fashion that is similar to peritoneal dialysis and has shown considerable promise in animal models. We have conducted a review of the available literature and techniques, including intraperitoneal perfluorocarbons, intraperitoneal jet ventilation, a continuous low-pressure oxygen system (PEROX) and the use of phospholipid-coated oxygen microbubbles (OMBs) through peritoneal microbubble oxygenation (PMO). We conclude that peritoneal oxygenation is a promising technique that warrants further investigation and might be used in clinical settings in the future.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"90 6","pages":"511-517"},"PeriodicalIF":1.8,"publicationDate":"2022-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10429142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using a Fibrinolysis Delivery Catheter in Pulmonary Embolism Treatment for Measurement of Pulmonary Artery Hemodynamics. 在肺栓塞治疗中使用纤溶输送导管测量肺动脉血流动力学。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-11-23 DOI: 10.3390/arm90060055
Abdelrahman Elhakim, Martin Knauth, Mohamed Elhakim, Ulrich Böhmer, Johannes Patzelt, Peter Radke

Background: Ultrasound-facilitated and catheter-directed low-dose fibrinolysis (EKOS) has shown favorable hemodynamic and safety outcomes in intermediate- to high-risk pulmonary embolism (PE) cases. Objectives: This prospective single-arm monocentric study assessed the effects of using a delivery catheter for fibrinolysis as a novel approach for acute intermediate- to high-risk patients on pulmonary artery hemodynamics PE. Methods: Forty-five patients (41 intermediate−high and 4 high risk) with computer tomography (CT)-confirmed PE underwent EKOS therapy. By protocol, a total of 6 mg of tissue-plasminogen activator (t-PA) was administered over 6 h in the pulmonary artery (unilateral 6 mg or bilateral 12 mg). Unfractionated heparin was provided periprocedurally. The primary safety outcome was death, as well as major and minor bleeding within 48 of procedure initiation and at 90 days. The primary effectiveness outcomes were: 1. to assess the difference in pulmonary artery pressure from baseline to 6 h post-treatment as a primary precise surrogate marker, and 2. to determine the echocardiographic RV/LV ratio from baseline to 48 h and at 90 days post-delivery. Results: Pulmonary artery pressure decreased by 15/6/10 mmHg (p < 0.001). The mean RV/LV ratio decreased from 1.2 ± 0.85 at baseline to 0.85 ± 0.12 at 48 and to 0.76 ± 0.13 at 90 days (p < 0.001). Five patients (11%) died within 90 days of therapy. Conclusions and Highlights: Pulmonary artery hemodynamics were assessed using a delivery catheter for fibrinolysis, which is reproducible for identifying PE at risk of adverse outcomes. The results matched the right heart catheter results in EKOS and Heparin arm of Ultima trial, thereby confirming the validity of this potential diagnostic tool to assess therapy effectiveness and thereby reduce additional procedure-related complications, hospital residency, and economics. These results stress the importance of having an interdisciplinary team involved in the management of PE to evaluate the quality of life of these patients and this protocol shortens ICU admission to 6 h.

背景:超声引导和导管引导下的低剂量纤溶(EKOS)在中高风险性肺栓塞(PE)病例中显示出良好的血流动力学和安全性结果。目的:这项前瞻性单臂单中心研究评估了使用输送导管进行纤溶治疗作为急性中高危患者肺动脉血流动力学PE的一种新方法的效果。方法:45例计算机断层扫描(CT)确诊的PE患者(41例中高危,4例高危)接受EKOS治疗。通过方案,在肺动脉中给予6mg组织纤溶酶原激活剂(t-PA)超过6小时(单侧6mg或双侧12mg)。围手术期给予未分离肝素。主要安全结局是死亡,以及手术开始后48天和90天内的大出血和小出血。主要疗效指标为:1。评估肺动脉压从基线到治疗后6小时作为主要精确替代指标的差异;以确定超声心动图左室/左室比从基线到48小时和分娩后90天。结果:肺动脉压降低15/6/10 mmHg (p < 0.001)。平均RV/LV比值从基线时的1.2±0.85下降到48天时的0.85±0.12和90天时的0.76±0.13 (p < 0.001)。5名患者(11%)在治疗90天内死亡。结论和重点:肺动脉血流动力学评估使用输送导管纤维蛋白溶解,这是可重复的,以确定PE的不良后果的风险。结果与Ultima试验中EKOS和肝素组的右心导管结果相符,从而证实了这一潜在诊断工具的有效性,以评估治疗效果,从而减少额外的手术相关并发症、住院率和经济性。这些结果强调了跨学科团队参与PE管理的重要性,以评估这些患者的生活质量,该方案将ICU住院时间缩短至6小时。
{"title":"Using a Fibrinolysis Delivery Catheter in Pulmonary Embolism Treatment for Measurement of Pulmonary Artery Hemodynamics.","authors":"Abdelrahman Elhakim,&nbsp;Martin Knauth,&nbsp;Mohamed Elhakim,&nbsp;Ulrich Böhmer,&nbsp;Johannes Patzelt,&nbsp;Peter Radke","doi":"10.3390/arm90060055","DOIUrl":"https://doi.org/10.3390/arm90060055","url":null,"abstract":"<p><p>Background: Ultrasound-facilitated and catheter-directed low-dose fibrinolysis (EKOS) has shown favorable hemodynamic and safety outcomes in intermediate- to high-risk pulmonary embolism (PE) cases. Objectives: This prospective single-arm monocentric study assessed the effects of using a delivery catheter for fibrinolysis as a novel approach for acute intermediate- to high-risk patients on pulmonary artery hemodynamics PE. Methods: Forty-five patients (41 intermediate−high and 4 high risk) with computer tomography (CT)-confirmed PE underwent EKOS therapy. By protocol, a total of 6 mg of tissue-plasminogen activator (t-PA) was administered over 6 h in the pulmonary artery (unilateral 6 mg or bilateral 12 mg). Unfractionated heparin was provided periprocedurally. The primary safety outcome was death, as well as major and minor bleeding within 48 of procedure initiation and at 90 days. The primary effectiveness outcomes were: 1. to assess the difference in pulmonary artery pressure from baseline to 6 h post-treatment as a primary precise surrogate marker, and 2. to determine the echocardiographic RV/LV ratio from baseline to 48 h and at 90 days post-delivery. Results: Pulmonary artery pressure decreased by 15/6/10 mmHg (p < 0.001). The mean RV/LV ratio decreased from 1.2 ± 0.85 at baseline to 0.85 ± 0.12 at 48 and to 0.76 ± 0.13 at 90 days (p < 0.001). Five patients (11%) died within 90 days of therapy. Conclusions and Highlights: Pulmonary artery hemodynamics were assessed using a delivery catheter for fibrinolysis, which is reproducible for identifying PE at risk of adverse outcomes. The results matched the right heart catheter results in EKOS and Heparin arm of Ultima trial, thereby confirming the validity of this potential diagnostic tool to assess therapy effectiveness and thereby reduce additional procedure-related complications, hospital residency, and economics. These results stress the importance of having an interdisciplinary team involved in the management of PE to evaluate the quality of life of these patients and this protocol shortens ICU admission to 6 h.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"90 6","pages":"483-499"},"PeriodicalIF":1.8,"publicationDate":"2022-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10860844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations. 慢性阻塞性肺疾病伴感染性加重患者治疗过程中血清免疫球蛋白G亚类的变化
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-11-23 DOI: 10.3390/arm90060056
Thang Ba Ta, Tien Tran Viet, Kien Xuan Nguyen, Cong Hai Nguyen, Hoan Ngoc Vu, Tuan Dinh Le, Son Tien Nguyen, Hung Khac Dong, Nhung Kim Thi Pham, Bang Ngoc Dao

Introduction: Despite the theoretical importance of serum immunoglobulin (Ig) in the outcome of COPD exacerbations, the existing evidence for this has not been enough. This study was performed to evaluate changes in serum Ig levels and their relationship with outcomes of acute infectious exacerbations in patients with COPD. Methods: The prospective study was conducted at Military Hospital 103 from August 2017 to April 2019. Group D patients with COPD with infectious exacerbation were selected for participation in the study. The control group consisted of 30 healthy people. The patients were provided clinical examination and laboratory service; simultaneously, we measured their serum Ig levels (total IgG, IgG1, IgG2, IgG3, IgG4) at two time points: at admission (T1) and the final health outcome (T2). Results: The median levels of total IgG in patients at times T1 and T2 were significantly lower compared with those in the healthy group (1119.3 mg/dL and 1150.6 mg/dL compared with 2032.2 mg/dL) (p < 0.001). Regarding changes among IgG subclasses, the IgG1, IgG3, and IgG4 levels measured at T1 and T2 were reduced significantly compared with the control group (p < 0.05); the IgG3 levels at T1 were significantly higher than those at T2. IgG3 levels in patients with life-threatening exacerbations were significantly lower than the remaining ones (24.6 (26.8−155.5) mg/dL and 25.6 (29.5−161.2) mg/dL, respectively, p = 0.023). Conclusions: In group D patients with COPD with infectious exacerbations, there was a decrease in the serum IgG, IgG1, IgG3, and IgG4 levels. IgG3 levels were associated with the severity of COPD exacerbation.

尽管血清免疫球蛋白(Ig)在COPD恶化结果中的理论重要性,但现有的证据还不够。本研究旨在评估慢性阻塞性肺病患者血清Ig水平的变化及其与急性感染性加重结局的关系。方法:前瞻性研究于2017年8月至2019年4月在103部队医院进行。选择D组COPD合并感染性加重患者参与研究。对照组由30名健康人组成。为患者提供临床检查和化验服务;同时,我们在入院(T1)和最终健康结局(T2)两个时间点测量了他们的血清Ig水平(总IgG、IgG1、IgG2、IgG3、IgG4)。结果:患者T1和T2时总IgG中位水平显著低于健康组(1119.3 mg/dL和1150.6 mg/dL分别低于健康组2032.2 mg/dL) (p < 0.001)。各组IgG亚类变化中,T1、T2时IgG1、IgG3、IgG4水平较对照组显著降低(p < 0.05);T1时IgG3水平明显高于T2时。危及生命加重期患者的IgG3水平显著低于其余患者(分别为24.6(26.8−155.5)mg/dL和25.6(29.5−161.2)mg/dL, p = 0.023)。结论:D组COPD合并感染性加重患者血清IgG、IgG1、IgG3、IgG4水平降低。IgG3水平与COPD恶化的严重程度相关。
{"title":"Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations.","authors":"Thang Ba Ta,&nbsp;Tien Tran Viet,&nbsp;Kien Xuan Nguyen,&nbsp;Cong Hai Nguyen,&nbsp;Hoan Ngoc Vu,&nbsp;Tuan Dinh Le,&nbsp;Son Tien Nguyen,&nbsp;Hung Khac Dong,&nbsp;Nhung Kim Thi Pham,&nbsp;Bang Ngoc Dao","doi":"10.3390/arm90060056","DOIUrl":"https://doi.org/10.3390/arm90060056","url":null,"abstract":"<p><p>Introduction: Despite the theoretical importance of serum immunoglobulin (Ig) in the outcome of COPD exacerbations, the existing evidence for this has not been enough. This study was performed to evaluate changes in serum Ig levels and their relationship with outcomes of acute infectious exacerbations in patients with COPD. Methods: The prospective study was conducted at Military Hospital 103 from August 2017 to April 2019. Group D patients with COPD with infectious exacerbation were selected for participation in the study. The control group consisted of 30 healthy people. The patients were provided clinical examination and laboratory service; simultaneously, we measured their serum Ig levels (total IgG, IgG1, IgG2, IgG3, IgG4) at two time points: at admission (T1) and the final health outcome (T2). Results: The median levels of total IgG in patients at times T1 and T2 were significantly lower compared with those in the healthy group (1119.3 mg/dL and 1150.6 mg/dL compared with 2032.2 mg/dL) (p < 0.001). Regarding changes among IgG subclasses, the IgG1, IgG3, and IgG4 levels measured at T1 and T2 were reduced significantly compared with the control group (p < 0.05); the IgG3 levels at T1 were significantly higher than those at T2. IgG3 levels in patients with life-threatening exacerbations were significantly lower than the remaining ones (24.6 (26.8−155.5) mg/dL and 25.6 (29.5−161.2) mg/dL, respectively, p = 0.023). Conclusions: In group D patients with COPD with infectious exacerbations, there was a decrease in the serum IgG, IgG1, IgG3, and IgG4 levels. IgG3 levels were associated with the severity of COPD exacerbation.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"90 6","pages":"500-510"},"PeriodicalIF":1.8,"publicationDate":"2022-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10855259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Survival Trend of Tuberculosis Patients and Risk Factors Associated with Mortality and Developing Drug-Resistant Tuberculosis in Hospital Pulau Pinang, Malaysia: A Retrospective Study. 马来西亚普劳槟榔屿医院肺结核病人的生存趋势以及与死亡率和产生耐药性肺结核有关的风险因素:一项回顾性研究。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-11-14 DOI: 10.3390/arm90060054
Aseel Rezeq Yaghi, Heba Saleh Shaheed, Sabariah Noor Harun, Irfhan Ali Hyder Ali, Amer Hayat Khan

Background: Multidrug resistance TB (MDR-TB) has emerged as a public health issue worldwide, and the mortality rate is worrying. Therefore, this study was conducted to investigate the factors related to MDR-TB occurrence and the survival experience of TB patients.

Methods: A retrospective cohort study was conducted at Hospital Pulau Pinang in Malaysia. Medical records of active TB patients from 2014-2018 were reviewed. Cox regression was used to identify the factors associated with MDR-TB development and mortality among TB patients.

Results: The patients had a mean age of 48.84 ± 16.713 years, and a majority of the Chinese race (46.4%). Out of 351 TB patients, 325 (92.6%) were drug-susceptible TB, and 26 (7.4%) were diagnosed with MDR-TB. Among drug-susceptible TB patients, 245 (75.4%) achieved successful outcomes, and 73 (22.5%) passed away. In multivariable Cox regression, drug addiction, levels of white blood cells, urea, platelets, and albumin were significantly associated with death. Relapsed TB, alcohol consumption, and being single were significant risk factors for MDR-TB development.

Conclusion: Patients achieved a success rate of 75.4%, which is encouraging but still far below the WHO target (at least an 85% success rate) and has room for further improvement.

背景:耐多药结核病(MDR-TB)已成为全球公共卫生问题,其死亡率令人担忧。因此,本研究旨在调查与 MDR-TB 发生相关的因素以及结核病患者的生存经历:方法:在马来西亚的普劳槟榔屿医院开展了一项回顾性队列研究。研究回顾了 2014-2018 年间活动性肺结核患者的医疗记录。结果:患者平均年龄为48岁,平均病死率为1.5%:患者的平均年龄为(48.84 ± 16.713)岁,大部分为华裔(46.4%)。在 351 名肺结核患者中,325 人(92.6%)为药物敏感型肺结核,26 人(7.4%)被确诊为 MDR-TB 患者。在对药物敏感的肺结核患者中,245 人(75.4%)成功治愈,73 人(22.5%)去世。在多变量考克斯回归中,吸毒成瘾、白细胞、尿素、血小板和白蛋白水平与死亡显著相关。结核病复发、饮酒和单身是耐多药结核病发展的重要风险因素:患者的成功率为 75.4%,虽然令人鼓舞,但仍远低于世界卫生组织的目标(至少 85% 的成功率),仍有进一步提高的空间。
{"title":"Survival Trend of Tuberculosis Patients and Risk Factors Associated with Mortality and Developing Drug-Resistant Tuberculosis in Hospital Pulau Pinang, Malaysia: A Retrospective Study.","authors":"Aseel Rezeq Yaghi, Heba Saleh Shaheed, Sabariah Noor Harun, Irfhan Ali Hyder Ali, Amer Hayat Khan","doi":"10.3390/arm90060054","DOIUrl":"10.3390/arm90060054","url":null,"abstract":"<p><strong>Background: </strong>Multidrug resistance TB (MDR-TB) has emerged as a public health issue worldwide, and the mortality rate is worrying. Therefore, this study was conducted to investigate the factors related to MDR-TB occurrence and the survival experience of TB patients.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted at Hospital Pulau Pinang in Malaysia. Medical records of active TB patients from 2014-2018 were reviewed. Cox regression was used to identify the factors associated with MDR-TB development and mortality among TB patients.</p><p><strong>Results: </strong>The patients had a mean age of 48.84 ± 16.713 years, and a majority of the Chinese race (46.4%). Out of 351 TB patients, 325 (92.6%) were drug-susceptible TB, and 26 (7.4%) were diagnosed with MDR-TB. Among drug-susceptible TB patients, 245 (75.4%) achieved successful outcomes, and 73 (22.5%) passed away. In multivariable Cox regression, drug addiction, levels of white blood cells, urea, platelets, and albumin were significantly associated with death. Relapsed TB, alcohol consumption, and being single were significant risk factors for MDR-TB development.</p><p><strong>Conclusion: </strong>Patients achieved a success rate of 75.4%, which is encouraging but still far below the WHO target (at least an 85% success rate) and has room for further improvement.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"90 6","pages":"467-482"},"PeriodicalIF":1.8,"publicationDate":"2022-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10787956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of Cytokines and Proliferation Marker Ki-67 in Chronic Rhinosinusitis with Recurring Nasal Polyps 慢性鼻窦炎伴复发性鼻息肉患者细胞因子及增殖标志物Ki-67的研究
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-10-01 DOI: 10.3390/arm90050053
Rudolfs Janis Viksne, G. Sumeraga, M. Pilmane
Highlights What are the main findings? Cytokines are found in greater numbers in subepithelial connective tissue rather than epithelial cells in nasal polyps. IL-6 is an important factor in the pathogenesis of recurrent nasal polyps. What are the implications of the main finding? IL-6 was established as an important factor for further research in CRSwNP Possible future clinical implications, yet further research is necessary. Abstract Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammation of the mucosa of the nose and paranasal sinuses with the presence of polyps, affecting between 2.7% and 4.4% of the population. Cytokine analysis has become important in research on inflammatory mechanisms in CRSwNP. Therefore, our aim is to investigate the complex appearance, relative distribution, and interlinks of IL-1, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, and Ki-67 in CRSwNP. Methods: Samples of nasal polyps were obtained from 19 patients with previously diagnosed CRSwNP and the recurrence of polyps after previous surgeries. The control group consisted of samples from 17 otherwise healthy individuals with isolated nasal septum deviations. Tissues were stained for previously mentioned cytokines and Ki-67 immunohistochemically. Results: Polyp samples showed an increased presence of cytokines in subepithelial connective tissue and a decreased appearance in epithelium when compared to controls. There were several very strong, strong, and moderate correlations among factors. Conclusions: IL-6 strongly correlates with other cytokines as well as with the proliferation marker Ki-67, which suggests significant stimulation of this regulatory cytokine and its possible involvement in the pathogenesis of recurrent nasal polyps. IL-4, IL-7, IL-10, and IL-12 correlate with Ki-67, which suggests the possible involvement of these cytokines in tissue cell proliferation in the case of recurrent nasal polyps.
亮点主要发现是什么?在鼻息肉中,上皮下结缔组织中的细胞因子数量比上皮细胞多。IL-6是复发性鼻息肉发病机制中的一个重要因素。主要发现的含义是什么?IL-6被确定为CRSwNP进一步研究的重要因素。可能的未来临床意义,但有必要进行进一步研究。摘要背景:慢性鼻窦炎伴鼻息肉(CRSwNP)是一种伴有息肉的鼻粘膜和鼻窦慢性炎症,影响2.7%至4.4%的人群。细胞因子分析在CRSwNP炎症机制的研究中具有重要意义。因此,我们的目的是研究CRSwNP中IL-1、IL-4、IL-6、IL-7、IL-8、IL-10、IL-12和Ki-67的复杂外观、相对分布和相互联系。方法:从19例既往诊断为CRSwNP和既往手术后息肉复发的患者中获取鼻息肉样本。对照组由17名患有孤立鼻中隔偏曲的健康个体的样本组成。对组织进行先前提到的细胞因子和Ki-67免疫组织化学染色。结果:与对照组相比,息肉样品显示上皮下结缔组织中细胞因子的存在增加,上皮中细胞因子出现减少。因素之间存在几个非常强、强和中等的相关性。结论:IL-6与其他细胞因子以及增殖标志物Ki-67密切相关,这表明这种调节性细胞因子的显著刺激及其可能参与复发性鼻息肉的发病机制。IL-4、IL-7、IL-10和IL-12与Ki-67相关,这表明这些细胞因子可能参与复发性鼻息肉的组织细胞增殖。
{"title":"Characterization of Cytokines and Proliferation Marker Ki-67 in Chronic Rhinosinusitis with Recurring Nasal Polyps","authors":"Rudolfs Janis Viksne, G. Sumeraga, M. Pilmane","doi":"10.3390/arm90050053","DOIUrl":"https://doi.org/10.3390/arm90050053","url":null,"abstract":"Highlights What are the main findings? Cytokines are found in greater numbers in subepithelial connective tissue rather than epithelial cells in nasal polyps. IL-6 is an important factor in the pathogenesis of recurrent nasal polyps. What are the implications of the main finding? IL-6 was established as an important factor for further research in CRSwNP Possible future clinical implications, yet further research is necessary. Abstract Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammation of the mucosa of the nose and paranasal sinuses with the presence of polyps, affecting between 2.7% and 4.4% of the population. Cytokine analysis has become important in research on inflammatory mechanisms in CRSwNP. Therefore, our aim is to investigate the complex appearance, relative distribution, and interlinks of IL-1, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, and Ki-67 in CRSwNP. Methods: Samples of nasal polyps were obtained from 19 patients with previously diagnosed CRSwNP and the recurrence of polyps after previous surgeries. The control group consisted of samples from 17 otherwise healthy individuals with isolated nasal septum deviations. Tissues were stained for previously mentioned cytokines and Ki-67 immunohistochemically. Results: Polyp samples showed an increased presence of cytokines in subepithelial connective tissue and a decreased appearance in epithelium when compared to controls. There were several very strong, strong, and moderate correlations among factors. Conclusions: IL-6 strongly correlates with other cytokines as well as with the proliferation marker Ki-67, which suggests significant stimulation of this regulatory cytokine and its possible involvement in the pathogenesis of recurrent nasal polyps. IL-4, IL-7, IL-10, and IL-12 correlate with Ki-67, which suggests the possible involvement of these cytokines in tissue cell proliferation in the case of recurrent nasal polyps.","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"90 1","pages":"451 - 466"},"PeriodicalIF":1.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45909644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis 波兰呼吸学会诊断和治疗进行性纤维化间质肺疾病(非特发性肺纤维化)指南
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2022-10-01 DOI: 10.3390/arm90050052
W. Piotrowski, M. Martusewicz-Boros, A. Białas, A. Barczyk, B. Batko, K. Błasińska, P. Boros, K. Górska, P. Grzanka, E. Jassem, D. Jastrzębski, Janina Kaczyńska, O. Kowal-Bielecka, E. Kucharz, J. Kuś, B. Kuźnar-Kamińska, B. Kwiatkowska, R. Langfort, K. Lewandowska, B. Maćkiewicz, S. Majewski, J. Makowska, J. Miłkowska-Dymanowska, E. Puścińska, A. Siemińska, M. Sobiecka, Renata Soroka-Dąda, M. Szołkowska, E. Wiatr, D. Ziora, P. Śliwiński
Highlights The working group of the Polish Respiratory Society (PTChP) developed guidelines for diagnosis and treatment of PF-ILD. What are the main findings? A multidisciplinary team should be involved in the diagnosis and treatment of progressive pulmonary fibrosis. Nintedanib alone or in combination with immunomodulatory drugs is recommended for the treatment of PF-ILD, especially when an earlier solely immunomodulatory treatment was ineffective. What are the implications of the main finding? This document is a guide for Polish medical personnel involved in the diagnosis and treatment of PF-ILD. The guidelines will serve as an aid for healthcare organizers in Poland on how to optimize the diagnostic and therapeutic processes for ILD and improve the access of patients to modern therapy. Abstract The recommendations were developed as answers to previously formulated questions concerning everyday diagnostic and therapeutic challenges. They were developed based on a review of the current literature using the GRADE methodology. The experts suggest that PF-ILD be diagnosed based on a combination of different criteria, such as the aggravation of symptoms, progression of radiological lesions, and worsening of lung function test parameters. The experts recommend a precise diagnosis of an underlying disease, with serological testing for an autoimmune disease always being included. The final diagnosis should be worked out by a multidisciplinary team (MDT). Patients with an interstitial lung disease other than IPF who do not meet the criteria for the progressive fibrosis phenotype should be monitored for progression, and those with systemic autoimmune diseases should be regularly monitored for signs of interstitial lung disease. In managing patients with interstitial lung disease associated with autoimmune diseases, an opinion of an MDT should be considered. Nintedanib rather than pirfenidon should be introduced in the event of the ineffectiveness of the therapy recommended for the treatment of the underlying disease, but in some instances, it is possible to start antifibrotic treatment without earlier immunomodulatory therapy. It is also admissible to use immunomodulatory and antifibrotic drugs simultaneously. No recommendations were made for or against termination of anti-fibrotic therapy in the case of noted progression during treatment of a PF-ILD other than IPF. The experts recommend that the same principles of non-pharmacological and palliative treatment and eligibility for lung transplantation should be applied to patients with an interstitial lung disease other than IPF with progressive fibrosis as in patients with IPF.
波兰呼吸学会(PTChP)工作组制定了PF-ILD的诊断和治疗指南。主要发现是什么?进行性肺纤维化的诊断和治疗应由多学科团队参与。尼达尼布单独或联合免疫调节药物被推荐用于治疗PF-ILD,特别是当早期单独免疫调节治疗无效时。主要发现的含义是什么?本文件是波兰医疗人员参与诊断和治疗PF-ILD的指南。该指南将为波兰的卫生保健组织者提供帮助,帮助他们优化ILD的诊断和治疗过程,并改善患者获得现代治疗的机会。这些建议是为了回答以前制定的关于日常诊断和治疗挑战的问题。它们是基于使用GRADE方法对当前文献的回顾而开发的。专家建议,PF-ILD的诊断应结合不同的标准,如症状的加重、放射学病变的进展和肺功能测试参数的恶化。专家们建议对潜在疾病进行精确诊断,同时对自身免疫性疾病进行血清学检测。最终诊断应由多学科小组(MDT)作出。对于不符合进行性纤维化表型标准的IPF以外的间质性肺病患者,应监测其进展情况,对于患有全身性自身免疫性疾病的患者,应定期监测间质性肺病的迹象。在管理与自身免疫性疾病相关的间质性肺疾病患者时,应考虑MDT的意见。如果推荐的治疗潜在疾病的方法无效,则应采用尼达尼布而不是吡非尼顿,但在某些情况下,可以在不进行早期免疫调节治疗的情况下开始抗纤维化治疗。同时使用免疫调节和抗纤维化药物也是允许的。在PF-ILD治疗期间除IPF外出现明显进展的情况下,没有建议支持或反对终止抗纤维化治疗。专家建议,非药物治疗和姑息治疗以及肺移植资格的原则应适用于除IPF患者外的间质性肺疾病伴进行性纤维化患者。
{"title":"Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis","authors":"W. Piotrowski, M. Martusewicz-Boros, A. Białas, A. Barczyk, B. Batko, K. Błasińska, P. Boros, K. Górska, P. Grzanka, E. Jassem, D. Jastrzębski, Janina Kaczyńska, O. Kowal-Bielecka, E. Kucharz, J. Kuś, B. Kuźnar-Kamińska, B. Kwiatkowska, R. Langfort, K. Lewandowska, B. Maćkiewicz, S. Majewski, J. Makowska, J. Miłkowska-Dymanowska, E. Puścińska, A. Siemińska, M. Sobiecka, Renata Soroka-Dąda, M. Szołkowska, E. Wiatr, D. Ziora, P. Śliwiński","doi":"10.3390/arm90050052","DOIUrl":"https://doi.org/10.3390/arm90050052","url":null,"abstract":"Highlights The working group of the Polish Respiratory Society (PTChP) developed guidelines for diagnosis and treatment of PF-ILD. What are the main findings? A multidisciplinary team should be involved in the diagnosis and treatment of progressive pulmonary fibrosis. Nintedanib alone or in combination with immunomodulatory drugs is recommended for the treatment of PF-ILD, especially when an earlier solely immunomodulatory treatment was ineffective. What are the implications of the main finding? This document is a guide for Polish medical personnel involved in the diagnosis and treatment of PF-ILD. The guidelines will serve as an aid for healthcare organizers in Poland on how to optimize the diagnostic and therapeutic processes for ILD and improve the access of patients to modern therapy. Abstract The recommendations were developed as answers to previously formulated questions concerning everyday diagnostic and therapeutic challenges. They were developed based on a review of the current literature using the GRADE methodology. The experts suggest that PF-ILD be diagnosed based on a combination of different criteria, such as the aggravation of symptoms, progression of radiological lesions, and worsening of lung function test parameters. The experts recommend a precise diagnosis of an underlying disease, with serological testing for an autoimmune disease always being included. The final diagnosis should be worked out by a multidisciplinary team (MDT). Patients with an interstitial lung disease other than IPF who do not meet the criteria for the progressive fibrosis phenotype should be monitored for progression, and those with systemic autoimmune diseases should be regularly monitored for signs of interstitial lung disease. In managing patients with interstitial lung disease associated with autoimmune diseases, an opinion of an MDT should be considered. Nintedanib rather than pirfenidon should be introduced in the event of the ineffectiveness of the therapy recommended for the treatment of the underlying disease, but in some instances, it is possible to start antifibrotic treatment without earlier immunomodulatory therapy. It is also admissible to use immunomodulatory and antifibrotic drugs simultaneously. No recommendations were made for or against termination of anti-fibrotic therapy in the case of noted progression during treatment of a PF-ILD other than IPF. The experts recommend that the same principles of non-pharmacological and palliative treatment and eligibility for lung transplantation should be applied to patients with an interstitial lung disease other than IPF with progressive fibrosis as in patients with IPF.","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"90 1","pages":"425 - 450"},"PeriodicalIF":1.8,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47873170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Advances in respiratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1